PMC:7796052 / 14789-15331 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"379","span":{"begin":54,"end":65},"obj":"Gene"},{"id":"380","span":{"begin":286,"end":297},"obj":"Gene"},{"id":"381","span":{"begin":415,"end":417},"obj":"Gene"},{"id":"382","span":{"begin":494,"end":496},"obj":"Gene"},{"id":"383","span":{"begin":280,"end":285},"obj":"Species"},{"id":"384","span":{"begin":193,"end":197},"obj":"Chemical"},{"id":"385","span":{"begin":384,"end":388},"obj":"Chemical"},{"id":"386","span":{"begin":523,"end":527},"obj":"Chemical"},{"id":"387","span":{"begin":247,"end":250},"obj":"CellLine"}],"attributes":[{"id":"A379","pred":"tao:has_database_id","subj":"379","obj":"Gene:624"},{"id":"A380","pred":"tao:has_database_id","subj":"380","obj":"Gene:624"},{"id":"A381","pred":"tao:has_database_id","subj":"381","obj":"Gene:3827"},{"id":"A382","pred":"tao:has_database_id","subj":"382","obj":"Gene:3827"},{"id":"A383","pred":"tao:has_database_id","subj":"383","obj":"Tax:9606"},{"id":"A384","pred":"tao:has_database_id","subj":"384","obj":"MESH:D000069285"},{"id":"A385","pred":"tao:has_database_id","subj":"385","obj":"MESH:D000069285"},{"id":"A386","pred":"tao:has_database_id","subj":"386","obj":"MESH:D000069285"},{"id":"A387","pred":"tao:has_database_id","subj":"387","obj":"CVCL:0213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Measurementent of the efficacy of the compound on the B2 receptor was carried out following the protocol described elsewhere [31]. The method is based on measuring differences in intracellular Ca2+ concentrations produced in diverse conditions on CHO cells expressing recombinant human B2 receptor by fluorometry. Agonism was measured through the capacity of the compound to increase Ca2+ concentration compared to BK (EC50 ~ 2.4 pM). Antagonism was measured through the capacity to antagonize BK based on the reduction of Ca2+ concentration."}

{"project":"LitCovid-sentences","denotations":[{"id":"T101","span":{"begin":0,"end":130},"obj":"Sentence"},{"id":"T102","span":{"begin":131,"end":313},"obj":"Sentence"},{"id":"T103","span":{"begin":314,"end":434},"obj":"Sentence"},{"id":"T104","span":{"begin":435,"end":542},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Measurementent of the efficacy of the compound on the B2 receptor was carried out following the protocol described elsewhere [31]. The method is based on measuring differences in intracellular Ca2+ concentrations produced in diverse conditions on CHO cells expressing recombinant human B2 receptor by fluorometry. Agonism was measured through the capacity of the compound to increase Ca2+ concentration compared to BK (EC50 ~ 2.4 pM). Antagonism was measured through the capacity to antagonize BK based on the reduction of Ca2+ concentration."}